The $2 Billion Bet AstraZeneca Is Making In Weight Loss

Shares of AZN stock popped Thursday after AstraZeneca (AZN) said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene. The news comes a day after Eli Lilly (LLY) gained U.S. approval for Zepbound, a rival to Novo Nordisk's (NVO) Wegovy. Both drugs target a…#azn #astrazeneca #elililly #lly #novonordisk #glp1 #allisongatlin #twitter #ibdagatlin #lookingfornextapple
Source: Reuters: Health - Category: Consumer Health News Source Type: news